Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05720325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dupilumab Effects Against Aeroallergen Challenge

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: estimated 88 to confirmed 96
    • Primary completion date: Nov 2026 to Nov 1, 2026
    • Study completion date: Nov 2027 to Nov 1, 2027
    v11
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v10
  3. Eligibility criteria expanded, about 9 wordsv9
  4. Eligibility criteria expanded, about 17 wordsv8
  5. Eligibility criteria shortened, about 13 wordsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: May 1, 2023 to Mar 29, 2023
    • Eligibility criteria shortened, about 54 words
    • Secondary endpoints: details revised at 2 of 2 entries
    v6
  2. Start date changed from estimate of May 2023 to May 1, 2023v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 2023 to May 2023
    • Site details revised at 2 of 2 sites
    v3
  5. Secondary endpoints revised (2)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Trial Details
NCT Number NCT05720325
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Asthma, Allergic
Related terms Asthma, Dust Mite Allergy
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov